An FDA panel dealt a blow to Dynavax Technologies on Thursday, raising concerns about the safety of the company's hepatitis B vaccine.
Dynavax Technologies ($DVAX) didn't get the safety nod it sought for its hepatitis B vaccine from FDA advisers Thursday, and its shares plummeted in extended trading. The Berkeley, CA-based biotech is seeking U.S. approval of the vaccine, Heplisav, which provides the developer its best shot at having a marketed product.
PerkinElmer ($PKI) has become a much bigger player in China's molecular clinical diagnostics market with the wrap-up of its $38 million acquisition of Shanghai Haoyuan Biotech Co.
5AM Ventures and Canaan Partners have joined forces to lead a $23 million A round for a startup antiviral biotech based in Radnor, PA. Novira Therapeutics is developing capsid-targeting antivirals for hepatitis B and HIV.
The U.S. Army has tapped Canada's MedMira ($MIR) to develop rapid diagnostics that can detect HIV and hepatitis B and C, a deal worth $4.2 million.
GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, and is usually a result of hepatitis B or C infection, or cirrhosis of the liver. Diagnosis is generally through CT or MRI scanning, but biomarkers could make diagnosis simpler, quicker, more effective and less expensive.
According to news reports, Cuba has eliminated viral hepatitis in its population under 15 through use of a vaccine against hepatitis B developed in Havana.
Telomere length in circulating DNA could be a blood-based test for patients who will progress from hepatitis B infection to liver cancer.
Alnylam Pharmaceuticals has sealed a new collaboration and licensing deal with Arrowhead Research Corp., giving it access to crucial drug delivery technology once owned by Swiss drug giant Roche.